Gilead Sciences ((GILD)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gilead Sciences is currently conducting a Phase 3 clinical study titled ‘A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations.’ The study aims to compare the effectiveness of zimberelimab and domvanalimab combined with chemotherapy against pembrolizumab with chemotherapy in improving overall survival for patients with untreated metastatic non-small cell lung cancer.
The interventions being tested include zimberelimab and domvanalimab, both administered intravenously, in combination with chemotherapy drugs such as carboplatin, cisplatin, paclitaxel, nab-paclitaxel, and pemetrexed. These treatments are intended to enhance patient survival rates compared to the current standard treatment involving pembrolizumab.
This study is designed as a randomized, open-label trial with a parallel intervention model, focusing on treatment as its primary purpose. There is no masking involved, meaning both researchers and participants know which treatments are being administered.
The study began on August 12, 2022, and is currently recruiting participants. The primary completion date is anticipated to be in 2025, with the last update submitted on August 21, 2025. These dates are crucial for tracking the study’s progress and potential impact on treatment standards.
From a market perspective, this study could significantly influence Gilead Sciences’ stock performance and investor sentiment, especially if the results show a marked improvement in patient outcomes. This could also affect the competitive landscape, as other companies in the oncology space may need to adjust their strategies in response to new data.
The study is ongoing, and further details are available on the ClinicalTrials portal.